Current Status of Preimplantation Genetic Diagnosis

Semra Kahraman, M.D., and Nacati Findikli, M.S.

ART and Reproductive Genetics Center, Istanbul Memorial Hospital, Istanbul, Turkey.

Since its first clinical application in early 90s, preimplantation genetic diagnosis (PGD) has become a powerful diagnostic procedure in clinical practice for avoiding the birth of an affected child as well as increasing the assisted reproductive technologies (ART) outcome. The technique involves the screening of preimplantation embryos for chromosomal abnormalities in certain indications such as advanced maternal age, repeated abortions and translocations, or for single gene defects, the majority of which are cystic fibrosis and thalassaemias. In this context, it becomes an alternative option for traditional prenatal diagnosis. So far, more than 1000 unaffected babies have been born after PGD, indicating that the procedure is safe and effective in prevention of genetic defects as well as increasing the ART outcome. Besides its diagnostic value and expanding indications such as cancer predisposition, dynamic mutations and late onset disorders, a new feature, namely preimplantation human leukocyte antigen (HLA) typing also demonstrates its novel therapeutic role in contemporary medicine. This article summarizes the recent status of PGD and discusses the current limitations and future perspectives associated with PGD techniques.

Key Words: PGD, ART, FISH

Introduction

It has been reported that nearly 50% of the cases with early pregnancy loss contain chromosomal abnormalities (Chandley 1984; Zenzes and Casper 1992; Jacobs ve Hassold 1995; Jobanputra et al., 2002). Although most of them are found to be eliminated before implantation, some anomalies such as trisomies of chromosomes 13, 18 and 21 can reach to blastocyst stage and even result in affected offspring (Sandalinas et al., 2001). Chromosomal aneuploidy has also been shown to increase under inappropriate stimulation protocols, suboptimal culture conditions, paternal factors and lack of certain growth factors (Munne et al., 1995; Janny and Menezo 1996; Kaye 1997; Moor et al., 1998; Calogero et al., 2003; Findikli et al., 2004).

Screening preimplantation embryos for certain chromosomal abnormalities is generally termed as PGD for aneuploidy screening (PGD-AS). It is based on the principle that detection and elimination of chromosomally abnormal embryos before embryo transfer could increase the reproductive efficiency in certain cases where aneuploidy is proven or likely to exert a negative effect (Munne et al., 1995; Benadiva et al., 1996; Kuliev et al., 2002). So far, applications of PGD for aneuploidy screening to a large extent involved indications such as advanced maternal age, repeated implantation failures and recurrent abortion (Munne et al., 1999; Gianaroli et al., 2001; Kuliev et al., 2002; Munne 2002; Wilton 2002; Pehlivan et al., 2003; Rubio et al., 2003; Kahraman et al., 2004a). Due to their increased risk of producing aneuploid gamete cells, carriers of structural abnormalities such as inversions and translocations are also among other PGD candidates. Improved clinical outcome with decreased early abortions after selection of abnormal embryos with PGD have recently been reported by different groups on reciprocal and Robertsonian translocations (Conn et al., 1998; Scriven et al., 1998, 2000; Munne et al., 1998, 2000; Findikli et al., 2003). Furthermore, the positive effect of PGD application on clinical results was recently documented in severe male infertility, Klinefelter’s syndrome and cases with abnormal gamete cell morphology, which are among other potential PGD indications (Gianaroli et al., 2001; Kahraman et al., 2000; 2003, 2004a, 2004b; Aran et al., 2004). The data accumulated on approximately 5000 PGD cycles having above indications clearly shows that the prevalence of chromosomal abnormalities in oocytes as well as at cleavage stages can be as high as 50-70%. Elimination of such embryos prevents the birth of a trisomic child, decreases the abortion as well as high order pregnancy rates and has a positive impact on implantation, validating the beneficial approach of selecting euploid embryos for embryo transfer in PGD for certain indications (IWGPG 2001; Munne et al., 2003; Kuliev and Verlinsky 2004a).

Preimplantation genetic diagnosis for single gene disorders

If one or both partners are carriers of a genetic
disease, in order to prevent the birth of an affected offspring, preimplantation embryos can be screened for a known genetic defect. Up to date, more than 300 healthy children have been born after approximately 1,500 PGD cycles for single gene disorders (ESHRE PGD Consortium Steering Committee 2000; Harper 2003). The technique involves the use of polymerase chain reaction (PCR) technology on a single cell and subsequent analysis by either conventional or advanced molecular genetics tools as DNA sequencing. Although, the first successful PGD application was based on sex selection for X-linked disorders, as the accuracy and the technical ease is improving, many autosomal dominant, autosomal recessive and X-linked genetic disorders, can now be diagnosed on preimplantation embryos by using one or two blastomeres obtained after embryo biopsy (Table I) (Handyside et al., 1990; Sermon 2002; Verlinsky and Kuliev 2002).

PGD for single gene disorders is further expanded to cancer predisposition, late onset disorders, or even serves as a therapeutic option for an affected sibling by preimplantation HLA typing (Verlinsky et al., 2001; Rechitsky et al., 2002, 2003). The latter is of importance, since it gives the unique opportunity for families in which an HLA compatible sibling can be born and its cord blood or bone marrow stem cells can be the ideal source for transplantation, leading to a successful restoration of the affected phenotype. Although the number of cases are currently limited to draw a general conclusion, reported results on 25 pregnancies obtained after 147 preimplantation HLA typing cycles are highly encouraging. However, certain clinical and patient specific factors can limit the successful pregnancy outcome. (Van de Velde et al., 2004; Fiorentino et al., 2004; Kuliev and Verlinsky, 2004b; Rechitsky et al., 2004; Kahraman et al., 2004c).

Besides its demonstrated diagnostic and therapeutic value, strict precautions should be taken, since several problems such as external contamination, allelic dropout or preferential amplification effect the results and the reliability of the technique. Nowadays, designing sterile and dedicated area with special labware, apparatus and technical improvements such as the introduction of nested and multiplex PCR systems seem to minimize these problems (Findlay et al., 1998; Lewis et al., 2001; Fiorentino et al., 2003).

**Methodology and technical approaches**

There are mainly two embryo development stages that sampling for PGD can be done: MII oocyte or prezygote stage and cleavage stage (Figure 1). First and second polar bodies of either an oocyte or fertilized zygote can be analyzed for a given chromosomal or DNA-sequence-based genetic defect. However, results obtained constitute only the maternal profile and do not give information regarding paternal contribution. On the other hand blastomere biopsy, reveals genetic information that is inherited from both parents. Advantages and disadvantages of these sampling stages on the analysis outcome are summarized in Table II.

Polar bodies are the by-products of the first and second meiotic divisions which appear after maturation of oocyte or fertilization. This type of analysis is usually preferred for the maternal indications which bring high aneuploidy risk in oocytes such as advanced maternal age and translocations in which female is the carrier. For other indications such as recurrent abortions, recurrent implantation failure and severe male infertility etc., evaluation of the blastomere is needed. In this case, biopsy is done by removing one or two blastomeres from a cleavage-stage embryo having 6-8 cells. Some centers use both polar body and blastoemere biopsy in order to increase the accuracy of the results (Kuliev et al., 2002). Also, biopsy can also be done at the blastocyst stage, involving the removal of multiple trophectoderm cells. Although the clinical data regarding the results are limited.

In all three stages, a partial opening on the zona pellucida should be created by either mechanical, chemical or laser-driven systems. A recent study compared the clinical outcome after different methods of zona opening and found insignificant differences of one technique to another (Joris et al., 2003). Therefore, subsequent aspiration of either polar bodies or a blastomere after zona opening is performed and obtained material is processed for either FISH (Figure 2) or single cell PCR. It has also been reported that, when compaction is observed during blastomere biopsy, short-term incubation of the embryo in Ca-Mg free media helps to facilitate the procedure (Kahraman et al., 2000). In order to study chromosomal abnormalities by FISH, biopsied samples are first fixed on a slide and subsequently analyzed after hybridization with probes.
Table II: Biopsy stages.

<table>
<thead>
<tr>
<th>Stages</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>First polar body biopsy</td>
<td>No known negative effect on embryo development.</td>
<td>Only one sample is available for analysis.</td>
</tr>
<tr>
<td>(M II oocyte stage)</td>
<td>More time is available for analysis before embryo transfer</td>
<td>Error rate is high.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Only maternal anomalies can be detected.</td>
</tr>
<tr>
<td>First and second polar body</td>
<td>Provides more accuracy compared to first polar body biopsy.</td>
<td>Limited time interval is available for biopsy.</td>
</tr>
<tr>
<td>biopsy (Prezygote stage)</td>
<td></td>
<td>Probability of chromosomal mosaicism</td>
</tr>
<tr>
<td></td>
<td>Both maternal and paternal anomalies can be analyzed.</td>
<td>Selection of blastoemeres with nuclei are required.</td>
</tr>
<tr>
<td></td>
<td>More accuracy can be obtained if two cells are used.</td>
<td>Limited time is available for analysis.</td>
</tr>
<tr>
<td></td>
<td>Large clinical data is available.</td>
<td>Number of embryos to be analyzed is decreased.</td>
</tr>
<tr>
<td></td>
<td>Multiple cells are available for analysis.</td>
<td>Representative or only trophectoderm lineage.</td>
</tr>
<tr>
<td></td>
<td>Embryo selection can be done at a later stage.</td>
<td>Clinical data is scarce.</td>
</tr>
<tr>
<td></td>
<td>Higher implantation and lower multiple pregnancy rates</td>
<td></td>
</tr>
<tr>
<td>Blastomere biopsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Cleavage stage)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trophectoderm biopsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Blastocyst stage)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1a. Polar body biopsy procedure.

Figure 1b. Blastomere biopsy procedure.
**Figure 2.** FISH images for corresponding aneuploidies: a) Trisomy 13, monosomy 21; b) Trisomy 18, monosomy 21; c) Trisomy 18; d) Triploidy (3n)

![FISH images](image1)

**Figure 3.** a) Robertsonian translocation 45 XY;rob t(13;14)(q10;q10) normal or balanced; b) Reciprocal translocation 46 XX;rcp t(11;22)(q25;q31) partial trisomy 11 (blue) and partial trisomy 22 (green); c) Reciprocal translocation 46 XX;rcp t(2;3)(q37;q27) normal or balanced; d) Blastomeres paired with mouse zygotes prior to electrofusion e) Fusion of two cells; f) FISH result on metaphase chromosomes after fusion.

![FISH images](image2)
specific for chromosomes to be analyzed. Several fixation methods are now available and their advantages and possible drawbacks such as the risk of misdiagnosis have recently been evaluated (Velila et al., 2002).

**Current limitations and future perspectives**

Although, the application of PGD becomes an invaluable tool for ART and clinical genetics, in order to increase its efficiency, several limitations should be overcome. First, the fact that only a limited subset of chromosomes can be analyzed in conventional FISH techniques restricts the successful outcome in PGD-AS applications (Munne and Weier 1996; Munne et al., 1999). This limitation is mainly attributed as technical, since it involves chromosome analysis on interphase nucleus, other than metaphase spreads which could allow karyotyping hence making the analysis of all the chromosomes possible. Interphase FISH also fails to determine whether the analyzed arrangement is normal or balanced in the case of structural chromosomal abnormalities. However, it has recently been reported that the application of nucleus conversion technique, which involves the fusion of a biopsied sample with a bovine or a mouse zygote successfully converted the interphase nucleus to a metaphase plate, giving reproducible and efficient results that can be analyzed for PGD (Evsikov and Verlinsky 1999; Willadsen et al., 1999). Representative images of this technique are shown in Figure 3. Application of this technique has recently been shown to be applied on 94 cycles, giving a 30.3% pregnancy rate (Verlinsky 2002).

Likewise, comparative genomic hybridization (CGH) has also been proposed as an alternative to interphase FISH. However, the time required (2-3 days) for the analysis requires cleavage stage embryos to be cryopreserved hence is not suitable for current clinical procedures. Although, successful pregnancies have been reported by CGH, cryopreservation after biopsy gives lower viability and poor ART outcome (Joris et al., 1999; Magli et al., 1999; Wilton et al., 2000; 2002). In the near future, improvements in the protocols, either shortening the time required for CGH or cryopreservation will create an alternative protocol for analyzing the whole set of chromosomes in a given embryo.

Another approach, which utilizes PCR and sequencing-based methods hence named as DNA fingerprinting has been developed and tested for the most common chromosomal abnormalities such as trisomy 21 (Katz et al., 2003). This technique initially included markers for 5 chromosomes. However, it needs to be determined whether this number can be sufficiently increased and be a powerful alternative to conventional FISH analysis. Recent developments in microarray technology have been another powerful tool in reproductive medicine. Although, the first impact would be the analysis of gene expression or mutation profiles on oocytes and embryos of different developmental stages which can provide potential targets for diagnosis. Development of customized microarrays, in which aneuploidy testing for all chromosomes could be possible, would boost the efficiency and eliminate the use of conventional FISH techniques. Several microarray prototypes have already been designed for standard aneuploidy testing and for Robertsonian translocations; however, the technique requires further clinical confirmations and improvements (Kuliev and Verlinsky 2004a).

Although, the successful results are obtained in more than 90% of the blastomeres analyzed during conventional FISH analysis, the presence of mosaicism is of a major concern in PGD-AS cycles. It has been reported that a certain rate of mosaicism is present in preimplantation embryos and this rate is even higher in certain cases such as patients with severe sperm defects and advanced maternal age. (Magli et al., 2000; Bialenska et al., 2002; Munne et al., 2002; Sherman et al., 2003). Obtained results can therefore carry a risk of representing false results, that is an embryo with majority of chromosomally normal blastomeres can be diagnosed as aneuploid and discarded from embryo transfer procedure.

**Conclusion**

In summary, cumulative analysis of more than 6000 PGD cycles performed to date indicates that application of PGD (i) prevents genetic disorders in couples at risk of having a child with a genetic disease, (ii) reduces the risk of high order pregnancies as well as repeated early abortions especially for translocation carrier couples and (iii) improves the ART outcome in poor prognosis patients such as women with increased maternal age. Expanding indications as well as novel approaches such as preimplantation HLA typing and the application of DNA microarray technologies also make PGD not only a diagnostic, but also a therapeutic tool for ART clinics. Although, there exist some limitations to be overcome with technical protocols, results of the accumulated clinical data is encouraging and the validity as well as accuracy have already been proven. Therefore, PGD facilities have already become an integrated part of an increased number of ART clinics worldwide.

**References**


